Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024104313> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2024104313 abstract "Background: A previous feasibility trial (E2104 – Ann Oncol 23(2):331–7,2012) suggested incorporation of B into anthracycline-containing adjuvant therapy was feasible but ongoing cardiac monitoring was required to define the true impact of B on cardiac function. Methods: Patients (pts) were assigned 1:2:2 to one of three treatment arms. In addition to doxorubicin and cyclophosphamide followed by weekly paclitaxel, patients received either placebo (Arm A – AC>T) or B during chemotherapy (Arm B - BAC>BT), or B during chemotherapy followed by B monotherapy (15 mg/kg q3wk) for an additional 10 cycles (Arm C – BAC>BT>B). Randomization was stratified and B dose adjusted for choice of AC schedule (classical q3wk − 15 mg/kg; dose dense(dd) q2 wk − 10 mg/kg). When indicated, radiation and hormonal therapy were administered concurrently with B (for Arm C pts). The primary cardiac endpoint was the incidence of clinically apparent cardiac dysfunction (CHF)defined as symptomatic decline in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) or symptomatic diastolic dysfunction as assessed by independent review. Cumulative toxicity data as of Jan 23, 2012 are presented. Results: From 11.07 to 2.11, 4994 pts were enrolled. Median age was 52; 80% received ddAC. Chemotherapy associated toxicities including myelosuppression (Grade 4 neutropenia 16/20/19%) and neuropathy (Grade ≥ 3 8/8/8%) were similar across all arms. Grade ≥ 3 hypertension/thrombosis/proteinuria/hemorrhage was reported by 7/3/ Conclusion: Incorporation of B into anthracycline and taxane containing adjuvant therapy results in a significant but small increase in clinical CHF. The rate of clinical CHF is similar to that predicted by E2104 (2.5–2.9%) and reported In the FDA label for anthracycline pre-treated pts(3.8%). No unexpected toxicities were encountered. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-17-01." @default.
- W2024104313 created "2016-06-24" @default.
- W2024104313 creator A5000487558 @default.
- W2024104313 creator A5029329131 @default.
- W2024104313 creator A5051542602 @default.
- W2024104313 creator A5059151961 @default.
- W2024104313 creator A5073184572 @default.
- W2024104313 creator A5082934211 @default.
- W2024104313 date "2012-12-15" @default.
- W2024104313 modified "2023-09-27" @default.
- W2024104313 title "Abstract P5-17-01: Bevacizumab (B) in the adjuvant treatment of breast cancer - first toxicity results from Eastern Cooperative Oncology Group trial E5103." @default.
- W2024104313 doi "https://doi.org/10.1158/0008-5472.sabcs12-p5-17-01" @default.
- W2024104313 hasPublicationYear "2012" @default.
- W2024104313 type Work @default.
- W2024104313 sameAs 2024104313 @default.
- W2024104313 citedByCount "0" @default.
- W2024104313 crossrefType "proceedings-article" @default.
- W2024104313 hasAuthorship W2024104313A5000487558 @default.
- W2024104313 hasAuthorship W2024104313A5029329131 @default.
- W2024104313 hasAuthorship W2024104313A5051542602 @default.
- W2024104313 hasAuthorship W2024104313A5059151961 @default.
- W2024104313 hasAuthorship W2024104313A5073184572 @default.
- W2024104313 hasAuthorship W2024104313A5082934211 @default.
- W2024104313 hasConcept C121608353 @default.
- W2024104313 hasConcept C126322002 @default.
- W2024104313 hasConcept C126894567 @default.
- W2024104313 hasConcept C141071460 @default.
- W2024104313 hasConcept C143998085 @default.
- W2024104313 hasConcept C2776694085 @default.
- W2024104313 hasConcept C2776755627 @default.
- W2024104313 hasConcept C2776802502 @default.
- W2024104313 hasConcept C2777063308 @default.
- W2024104313 hasConcept C2777802072 @default.
- W2024104313 hasConcept C2778198053 @default.
- W2024104313 hasConcept C530470458 @default.
- W2024104313 hasConcept C71924100 @default.
- W2024104313 hasConcept C78085059 @default.
- W2024104313 hasConcept C90924648 @default.
- W2024104313 hasConceptScore W2024104313C121608353 @default.
- W2024104313 hasConceptScore W2024104313C126322002 @default.
- W2024104313 hasConceptScore W2024104313C126894567 @default.
- W2024104313 hasConceptScore W2024104313C141071460 @default.
- W2024104313 hasConceptScore W2024104313C143998085 @default.
- W2024104313 hasConceptScore W2024104313C2776694085 @default.
- W2024104313 hasConceptScore W2024104313C2776755627 @default.
- W2024104313 hasConceptScore W2024104313C2776802502 @default.
- W2024104313 hasConceptScore W2024104313C2777063308 @default.
- W2024104313 hasConceptScore W2024104313C2777802072 @default.
- W2024104313 hasConceptScore W2024104313C2778198053 @default.
- W2024104313 hasConceptScore W2024104313C530470458 @default.
- W2024104313 hasConceptScore W2024104313C71924100 @default.
- W2024104313 hasConceptScore W2024104313C78085059 @default.
- W2024104313 hasConceptScore W2024104313C90924648 @default.
- W2024104313 hasLocation W20241043131 @default.
- W2024104313 hasOpenAccess W2024104313 @default.
- W2024104313 hasPrimaryLocation W20241043131 @default.
- W2024104313 hasRelatedWork W1965679184 @default.
- W2024104313 hasRelatedWork W1984022925 @default.
- W2024104313 hasRelatedWork W1990879993 @default.
- W2024104313 hasRelatedWork W1990985435 @default.
- W2024104313 hasRelatedWork W1994637727 @default.
- W2024104313 hasRelatedWork W1999670094 @default.
- W2024104313 hasRelatedWork W2012650942 @default.
- W2024104313 hasRelatedWork W2018306900 @default.
- W2024104313 hasRelatedWork W2033708075 @default.
- W2024104313 hasRelatedWork W2066757842 @default.
- W2024104313 hasRelatedWork W2087003997 @default.
- W2024104313 hasRelatedWork W2087883501 @default.
- W2024104313 hasRelatedWork W2164696024 @default.
- W2024104313 hasRelatedWork W2247131005 @default.
- W2024104313 hasRelatedWork W2322553328 @default.
- W2024104313 hasRelatedWork W2323783599 @default.
- W2024104313 hasRelatedWork W2327170850 @default.
- W2024104313 hasRelatedWork W2593203381 @default.
- W2024104313 hasRelatedWork W2792641003 @default.
- W2024104313 hasRelatedWork W3129208430 @default.
- W2024104313 isParatext "false" @default.
- W2024104313 isRetracted "false" @default.
- W2024104313 magId "2024104313" @default.
- W2024104313 workType "article" @default.